Existing backer GV returned to take part in a $100m round for the Stanford spinout that also attracted new investor Regeneron Pharmaceuticals.

DNAnexus, a US-based health informatics technology spinout of Stanford University, closed a $100m funding round on Tuesday backed by biotechnology firm Regeneron Pharmaceuticals and GV, an early-stage investment subsidiary of internet and technology conglomerate Alphabet.
Investment management firm Perceptive Advisors and venture capital firm Northpond Ventures co-led the round, which also featured Foresite Capital, TPG Capital and First Round Capital.
Founded in 2009, DNAnexus has created a software platform that enables researchers to store, analyse, manage and collaborate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in